Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Braz. j. infect. dis ; 23(1): 40-44, Jan.-Feb. 2019. tab
Article in English | LILACS | ID: biblio-1001500

ABSTRACT

ABSTRACT Hepatitis E virus (HEV) infection is one of the major public health problems in developing countries. HEV can cause chronic infections in immunocompromised individuals e.g. thalassemic patients with increased risk of morbidity and mortality. In addition there is possibility of HEV transmission through blood transfusion. Therefore, the present study aimed to investigate the seroprevalence and risk factors of HEV infection in β-thalassemic children. Methods: This cross-sectional study was conducted on 140 Egyptian children suffering from β-thalassemia, attending the hematology outpatient clinic from April to October 2016. Serum samples from patients were collected and anti-HEV antibodies; Immunoglobulin G (IgG) and Immunoglobulin M (IgM)were measured by enzyme-linked immunosorbent assay (ELISA). Results: The seroprevalence of HEV in β-thalassemic chidren was relatively high (27.15%). Anti-HEV IgG prevalence was 24.29% while that of IgM was 2.86%. There was significant association between HEV infection and age, residence, liver enzymes and amount of blood transfusion per year. Conclusions: Thalasemic patients are vulnerable to chronicity and increased risk of morbidity and mortality from HEV infection. Frequent assessment of liver enzymes in thalassemic patients to monitor subclinical HEV is recommended. Close monitoring and HEV screening of blood donations should be taken in consideration. Public awareness about HEV endemicity, modes of transmission, and risk hazards especially in high risk group should be done to reduce the disease burden.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Blood Transfusion , Hepatitis E/transmission , Hepatitis E/epidemiology , beta-Thalassemia/epidemiology , beta-Thalassemia/virology , Enzyme-Linked Immunosorbent Assay , Seroepidemiologic Studies , Prevalence , Cross-Sectional Studies , Multivariate Analysis , Risk Factors , Sex Distribution , Age Distribution , Egypt/epidemiology , Hepatitis B Antibodies/blood , Immunocompetence
2.
Braz. j. microbiol ; 46(3): 777-783, July-Sept. 2015. tab, ilus
Article in English | LILACS | ID: lil-755813

ABSTRACT

Vancomycin resistant Enterococcus faecium (VREF) ia an emerging and challenging nosocomial pathogen. This study aimed to determine the prevalence, risk factors and clonal relationships between different VREF isolates in the intensive care units (ICUs) of the university hospitals in our geographic location. This prospective study was conducted from July, 2012 until September, 2013 on 781 patients who were admitted to the ICUs of the Mansoura University Hospitals (MUHs), and fulfilled the healthcare-associated infection (HAI) criteria. Susceptibility testing was determined using the disk diffusion method. The clonal relationships were evaluated with pulsed field gel electrophoresis (PFGE). Out of 52 E. faecium isolates, 12 (23.1%) were vancomycin resistant. The significant risk factors for the VREF infections were: transfer to the ICU from a ward, renal failure, an extended ICU stay and use of third-generation cephalosporins, gentamicin, or ciprofloxacin. PFGE with the 12 isolates showed 9 different patterns; 3 belonged to the same pulsotype and another 2 carried a second pulsotypes. The similar pulsotypes isolates were isolated from ICUs of one hospital (EICUs); however, all of the isolates from the other ICUs had different patterns. Infection control policy, in conjunction with antibiotic stewardship, is important to combat VREF transmission in these high-risk patients.

.


Subject(s)
Humans , Anti-Bacterial Agents/therapeutic use , Cross Infection/epidemiology , Enterococcus faecium/drug effects , Gram-Positive Bacterial Infections/epidemiology , Vancomycin Resistance/physiology , Vancomycin-Resistant Enterococci/isolation & purification , Vancomycin/therapeutic use , Cephalosporins/therapeutic use , Ciprofloxacin/therapeutic use , Cross Infection/microbiology , DNA, Bacterial/genetics , Egypt/epidemiology , Enterococcus faecium/isolation & purification , Gentamicins/therapeutic use , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Intensive Care Units , Infection Control/methods , Microbial Sensitivity Tests , Prospective Studies , Renal Insufficiency , Risk Factors , Vancomycin-Resistant Enterococci/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL